Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myriad Weighs Separation Of Diagnostics, Drug Businesses

This article was originally published in The Gray Sheet

Executive Summary

As Myriad Genetics moves into a new phase - achieving profitability in fiscal 2008 for the first time - the company is seeking to develop a new corporate strategy to drive growth, which could include a sale or spin off of its pharma business, the firm said during its fiscal 2008 sales and earnings call Aug. 19
Advertisement

Related Content

Newly Independent Myriad Diagnostics Firm Will Pursue Product Acquisitions
Newly Independent Myriad Diagnostics Firm Will Pursue Product Acquisitions
Advertisement
UsernamePublicRestriction

Register

MT026518

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel